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E-mail: mhoffman@nih.govSalivary gland hypofunction causes significant morbidity and
loss of quality of life for head and neck cancer patients treated
with radiotherapy. Preventing hypofunction is an unmet ther-
apeutic need. We used an adeno-associated virus serotype 2
(AAV2) vector expressing the human neurotrophic factor neu-
rturin (CERE-120) to treat murine submandibular glands
either pre- or post-irradiation (IR). Treatment with CERE-
120 pre-IR, not post-IR, prevented hypofunction. RNA
sequencing (RNA-seq) analysis showed reduced gene expres-
sion associated with fibrosis and the innate and humoral im-
mune responses. We then used a minipig model with CERE-
120 treatment pre-IR and also compared outcomes of the
contralateral non-IR gland. Analysis of gene expression,
morphology, and immunostaining showed reduced IR-related
immune responses and improved secretory mechanisms.
CERE-120 prevented IR-induced hypofunction and restored
immune homeostasis, and there was a coordinated contralat-
eral gland response to either damage or treatment. CERE-120
gene therapy is a potential treatment for head and neck cancer
patients to influence communication among neuronal, im-
mune, and epithelial cells to prevent IR-induced salivary hypo-
function and restore immune homeostasis.
INTRODUCTION
Every year over 500,000 head and neck cancer (HNC) patients world-
wide receive radiotherapy treatment. A major complication is irre-
versible salivary gland hypofunction, due to the location of the glands
in the radiation field.1 Salivary hypofunction is associated with
increased oral and dental diseases, speech impairment, loss of taste,
and dysphagia, negatively impacting the patient’s quality of life. Cur-
rent therapies are palliative, but recent experimental approaches toMolecular Ther
This is an open access article under the CC BY-NC-restore function involve drugs affectingmammalian target of rapamy-
cin (mTOR) signaling,2,3 stem cell therapies to repair and/or regen-
erate functional tissue,4,5 and gene therapy to increase salivary func-
tion using viral vectors expressing aquaporins, which is currently in
human clinical trials.6,7
Exocrine glands, such as salivary and lacrimal glands, are highly inner-
vated and depend on the autonomic nervous system for proper devel-
opment, homeostasis, and functional regeneration after injury.8–11
Analysis of both human and murine submandibular glands (SMGs)
treated with irradiation (IR) show that epithelial-neuronal bidirectional
communication is impacted.Althoughneurons are considered relatively
IR-resistant, both mouse and human adult salivary glands damaged by
IRhave reduced parasympathetic innervation and a resulting imbalance
of sympathetic innervation.9 Saliva secretion requires innervation, sowe
used a neurotrophic factor, neurturin (NRTN), to prevent IR-induced
hypofunction by preserving innervation. NRTN is mainly secreted by
epithelial cells and is essential for parasympathetic neuronal survival
and axon growth.9,12 Not surprisingly, mice with genetic deletion of
either Nrtn or its receptor Gfra2 have fewer parasympathetic neurons
and reduced salivary gland innervation and function.13,14
Previously, we used an adenovirus serotype 5 vector expressing hu-
man NRTN delivered to murine SMGs 24 h before IR and analyzedapy: Methods & Clinical Development Vol. 18 September 2020 839
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CERE-120 Treatment Pre-IR, as Compared to Post-IR, Prevents
Long-Term Hyposalivation in Murine SMGs.
(A) Structure of the CERE-120 vector and the AAV2-GFP vector. (B) Schematic
illustration showing the two arms of the mouse study design. (C–E) Pilocarpine-
stimulated whole saliva was measured at 90 (C), 120 (D), or 300 (E) days post-IR in
AAV2-GFP (1010 vp/g) or CERE-120 (106, 108, and 1010 vp/g)-treated animals and
compared to non-IR mice (baseline). Saliva flow normalized to non-IR and shown as
%. Mean ± SEM. N = 5–10 mice. Dots represent saliva measurements of individual
mice. ANOVA with post hoc Dunnett’s test, ***p < 0.001; **p < 0.01, *p < 0.05, not
significant (ns) compared to non-IR.
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flow to non-irradiated (non-IR) glands, and expression of neuronal
markers, such as Ret, Tubb3, Vacht, and Th, increased, suggesting
that NRTN gene therapy may prevent IR-induced hypofunction.8
To advance this therapy toward the clinic, we needed to change the
viral vector to an adeno-associated virus serotype 2 (AAV2), which
has longer expression and fewer immune side effects and is now
the vector of choice for the current AAV2-AQP1 gene therapy clinical
trial7 (ClinicalTrials.gov: NCT02446249). Here, we used an AAV2-
based vector encoding human NRTN (CERE-120), which was made
by Ceregene, a part of Sangamo BioSciences. CERE-120 has been
used in humans in clinical trials for Parkinson’s disease (Clinical-
Trials.gov: NCT00252850 and NCT00400634).15,16 We tested
CERE-120 in mice pre- and post-IR and used RNA-seq analysis to
identify changes in gene expression. We moved to a large animal
porcine model, in which we could IR and treat only one parotid gland
(PG) but analyze saliva flow separately from the IR and contralateral
gland over time. The porcine PG is a translational model, used for
preclinical studies of efficacy and/or safety of drug and gene thera-
pies.3,17–20 Porcine PGs respond to IR in a similar manner to human
glands, in terms of gland anatomy, physiology, and the fibrotic and
inflammatory responses to IR.21 Together, our studies show that
CERE-120 may be an effective preventative gene therapy approach
to reduce salivary hypofunction by increasing innervation of the
gland, restoring immune homeostasis, and reducing the fibrotic
response to injury in submandibular and parotid salivary glands.
RESULTS
Gene TherapywithCERE-120 Treatment Pre-IR, as Compared to
Post-IR, Prevents Long-Term Hyposalivation in Murine SMGs
CERE-120 has coding sequences essential for replication removed to
generate a vector with only the non-coding inverted terminal repeats
(ITRs) of the AAV2 (Figure 1A).15 CERE-120 is an AAV2 vector that
consists of a CAG promoter replacing the coding sequences, a cDNA
region encoding the b-nerve growth factor pre-pro region (ppNGF)
fused to the mature region of human NRTN (hNRTN), and a polyA
sequence from human growth hormone (hGH). A panel of various
constructs generated the CAG promoter: a human cytomegalovirus
(CMV) enhancer, a chicken b-actin promoter and splice donor,
and a rabbit a-globin splice acceptor. The ppNGF promotes optimal
processing and secretion of hNRTN. As a control, an AAV2-GFP vec-
tor, which contains both AAV serotype 2 Capsid and ITR, and ex-
presses EGFP under the control of a CMV promoter, was purchased
from Vector Biolabs.mber 2020
Figure 2. Gland Anatomy and Morphology Improves after CERE-120 Pre-IR Treatment.
(A–C) Analysis of the body weight (g) (A), submandibular gland weight (mg), (B) and normalized ratio of gland weight to body weight (mg/g) (C) at 300 days of non-IR mice, and
mice treated with AAV2-GFP (1010 vp/g) or CERE-120 (106, 108, and 1010 vp/g) pre-IR. Dots represent measurement of individual mice. Mean ±SEM. N= 3–10mice. ANOVA
with post hoc Dunnett’s test, ***p < 0.001, *p < 0.05, not significant (ns) as compared to non-IR. (D) H&E and Masson’s trichrome (MT) staining of SMGs of non-IR mice, and
mice treated with AAV2-GFP (1010 vp/g) or CERE-120 (1010 vp/g) pre-IR. Images are representative of results from N R 3 mice. Scale bar, 50 mm.
www.moleculartherapy.orgAs AAV vectors in the salivary gland are reported to have slow ki-
netics of expression but result in prolonged expression,22 we treated
the murine glands with AAV2 10 days pre-IR (Figure 1B). For the
post-IR treatment groups, we used the treatment time frame that
had been used for murine experiments with AAV2-AQP1, which
was treatment 60 days post-IR when salivary flow was reduced.23
The CERE-120 (106, 108, or 1010 viral particles/gland [vp/g]) or
AAV2-GFP (1010 vp/g) vectors were administered by retro-ductal
infusion into SMGs at 60 days post-IR. A fractionated IR dose (6 
5 Gy) was used to induce hyposalivation,8 which was measured by
pilocarpine stimulation of whole saliva production. Saliva was
collected 90 days post-IR, and the IR control group produced
65% less saliva compared to the non-IR group (baseline), irrespec-
tive of whether the AAV2-GFP was delivered pre- or post-IR (Figures
1C–1E). All CERE-120 treatments pre-IR (106, 108, 1010 vp/g) re-
sulted in improved saliva flow compared to the IR-GFP group and
were similar to the non-IR group at 90 and 300 days. At 120 days,
there were differences in the 3 doses with CERE-120 at 108 and
1010 vp/g being similar to non-IR. In comparison, CERE-120 post-
IR treatment groups only showed similar saliva flow to the non-IR
group at 300 days, not at 90 and 120 days post-IR (Figures 1C and
1D). At 300 days, the post-IR-treated groups had more variability
in their response, although 4 of the 15 individual mice in the 3 groupsMolecular The(106, 108, 1010 vp/g) showed saliva levels similar to the non-IR group.
Further study is required to investigate what may be causing the vari-
ation in response to treatment post-IR treatment.
Gland Anatomy and Morphology Improves after CERE-120
Treatment Pre-IR
The body weights of mice from all treatment groups were similar to
the control (Figure 2A). IR treatment can reduce salivary gland weight
in animal models of irradiation.21 Accordingly, the SMG weights of
IR-GFP animals and the CERE-120 (108) group were reduced
compared to the non-IR group (Figure 2B), whereas the SMGweights
of CERE-120 (106 and 1010) groups were similar to non-IR SMGs.
When the gland weight was normalized to body weight, only the
IR-GFP group was reduced compared to the non-IR group, and all
doses of CERE-120 were similar to the non-IR group (Figure 2C).
In this IR-mouse model,24–26 IR-induced hyposalivation occurs
without a major loss in saliva-producing acinar cells. However, these
acinar cells do not function correctly, and in physiology experiments
of these IR cells the rate and extent of acinar cell volume decrease
upon stimulation of secretion is reduced.26 Histologically, this corre-
sponds to the appearance of large acinar cell clusters26 (Figure 2D;
Figure S1A, dotted line) in IR and AAV2-GFP-treated glands.rapy: Methods & Clinical Development Vol. 18 September 2020 841
Molecular Therapy: Methods & Clinical DevelopmentInterestingly, these large acinar clusters were not observed in IR-
CERE-treated mice, and many acini appeared similar in size to
non-IR glands. With fibrosis being a long-term side effect of IR,
AAV2-GFP glands also had large areas of periductal and perivascular
fibrosis, with collagen-rich connective tissue bundles appearing dark
blue with Masson’s trichrome (MT) staining (Figure 2D, arrow). In
IR-CERE-treated glands, there appeared to be fewer collagen-rich tis-
sue fibers than IR-GFP-treated glands and a similar number of fibers
along ducts and blood vessels comparable to non-IR glands. Taken
together, the data suggest that pre-IR treatment with CERE-120 im-
proves the weight of the gland and reduces the appearance of periduc-
tal fibrosis.
RNA Sequencing Analysis Shows that CERE-120 Treatment Pre-
IR Reduces the Expression of Genes Related to IR-Induced
Fibrosis and the Innate and Adaptive Humoral Immune
Responses
In order to investigate the transcriptional changes that occur with
CERE-120 treatment, we used RNA sequencing (RNA-seq) to
compare non-IR SMGs with both IR SMGs treated with AAV2-
GFP (IR-GFP) or CERE-120 (IR-CERE, 108 vg/g). By assigning a
nominal significance level of 0.05 and a log fold change of R2, we
identified 72 differentially expressed genes (DEGs) between non-IR
and IR-GFP-treated glands (Table 1). There were 31 DEGs upregu-
lated and 41 downregulated. We used qPCR to confirm some of the
gene expression changes from the RNA-seq data (Figure 3A). Exam-
ples of DEGs that were upregulated after IR-GFP are genes involved
inmatrix deposition, such as a collagen (Col23a1); matrix metallopro-
teinases (MMPs) involved in extracellular matrix (ECM) remodeling
(Mmp2,Mmp3);27 a cysteine peptidase inhibitor involved in ECM re-
modeling and fibrosis (Serping1);28,29 and injury-associated phospho-
lipase enzyme involved in epidermal growth factor receptor (EGFR)
signaling (Pla1a)30 (Figure 3A). Other upregulated genes are related
to inflammation and immune function (Clec12a, Cma1, Pld4, Lyz2).
A general observation was that treatment with CERE-120 (IR-
CERE) reduced gene expression to similar levels as the non-IR group
(Figure 3A). We also confirmed the downregulation of genes by
qPCR, for example, a neuronal voltage gated Na channel (Scn3a);
epidermal growth factor (Egf), which is expressed by epithelial gran-
ular ducts; and an epithelial semaphorin gene (Sema3c), potentially
involved in regulating innervation. As expected, acinar cell genes
related to salivary secretion, such as the embryonic form of mucin
19 (Smgc), amylase (Amy1, a salivary enzyme), and secernin (Scrn1,
a gene involved in exocytosis), were also reduced with IR-GFP treat-
ment. Another general observation was that treatment with CERE-
120 (IR-CERE) increased gene expression to levels similar to the
non-IR group. An exception in our qPCR analyses was amylase
(Amy1), a secreted enzyme that did not increase with CERE-120
treatment, and, as expected, E-cadherin (Cdh1), which is highly ex-
pressed in epithelial ducts, was not affected.
By comparing the RNA-seq data from IR-GFP with IR-CERE treat-
ment groups after 300 days post-IR, surprisingly, we only observed
38 DEGs (Table 2). There were 3 DEGs upregulated and 35 downregu-842 Molecular Therapy: Methods & Clinical Development Vol. 18 Septelated with CERE-120 treatment. These are interesting genes, because
they potentially highlight the secondary effects of CERE-120 in an irra-
diated microenvironment. There was a striking reduction of immuno-
globulin gene expression (9 out of 37 genes were immunoglobulins
[Igs]), suggesting that CERE-120 treatment reduces or resolves humor-
al immune response to IR. We speculate that CERE-120 helps restore
immune homeostasis in the gland. Further supporting this speculation,
there was reduced expression of complement related genes (C3, C1s1,
C3ar1, and F13a1), suggesting a secondary effect of CERE-120 on
the innate immunity after IR. There was also reduced expression of
genes involved in extracellular matrix proteolysis (Mmp2, Mmp3,
and Cma1). Interestingly, at this late stage (300 days) after IR and
CERE-120 treatment, there were no DEGs directly related to parasym-
pathetic or sympathetic function in the RNA-seq analysis; therefore, we
screened genes that were DEGs after adenovirus-NRTN treatment at
60 days in our previous work.8While there were no significant changes
in gene expression, there was variability in gene expression among
SMGs. Genes such as Vip, Adra2b, Vacht, and Tubb3 increased to a
level similar to control levels with IR-CERE treatment (Figure S2A).
Interestingly, when we compared the RNA-seq data from non-IR
with IR-CERE, there were even fewer DEGS, only 29, further suggest-
ing that gene expression after CERE-120 treatment is more similar to
non-IR glands (Table 3). There were 12 DEGs upregulated and 17
downregulated with IR-CERE treatment. However, most of these
genes (21) were present in the list of non-IR versus IR-GFP (Table
1), suggesting they may be regulated by IR. Of the remaining 8
DEGs, most are ubiquitously expressed, and two of them, Pdgfra
(platelet-derived growth factor receptor alpha) and Dpt (dermapon-
tin), are differentially expressed in IR-GFP compared to IR-CERE.
In order to identify any pathways or general biological processes
affected by the DEGs (Tables 1, 2, and 3), we used Gene Ontology
(GO) analysis.We confirmed that themost prominently altered biolog-
ical processes between non-IR and IR-GFP (72 DEGs) were the GO
terms, Secretion (GO: 0046903), Synapses (GO: 0045202), Regulation
of anatomical structure size (GO: 0090066), Regulation of cellular pro-
tein localization (GO: 1903827), and Intracellular transport (GO:
0046907) (Table 4), which is not surprising since gland hypofunction
affects secretion, glandular innervation, and secretory protein localiza-
tion and transport. However, the statistical analysis only showed false
discovery rate (FDR) q values of 3.82 102. What was more surpris-
ing was the GO analysis comparing IR-GFP with IR-CERE (38 DEGs,
Table 4). GO analysis highlighted significant overlap of DEGs in GO
terms such as Extracellular matrix (GO: 0031012), Collagen containing
extracellular matrix (GO: 0062023), Leukocyte mediated immunity
(GO: 0002443), Humoral immune response (GO: 0006959), Myeloid
leukocyte mediated immunity (GO: 0002444), Secretory granule
(GO: 0030141), Secretion (GO: 0046903), and Complement activation
(GO: 0006956). In this case the GO lists had lower FDR q values
ranging from 1.03 104 down to 8.41 1010. These GO terms sug-
gest that IR-CERE treatment could influence fibrosis, the immune
response within the gland, and secretion. There were significant over-
laps with the immune response, particularly the reduction in IgG genesmber 2020
Table 1. DEGs from RNA Sequencing Analysis of Murine SMGs: Non-IR
versus IR-GFP Treatments












































































Data of each group was compared to one another. The lists of differentially expressed
genes (DEGs) were generated after bioinformatic analysis of next-generation
sequencing data and a cut-off at Log2 fold change (FC) and adjusted p values < 0.05.
There were 72 DEGs comparing non-IR with IR-GFP.
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Molecular Theand the humoral response as well as myeloid immunity and comple-
ment activation, which is part of the innate immunity. The GO analysis
of the 29 DEGs in the non-IR versus IR-CERE group did not identify
any significant GO terms(Table 4).
We also investigated protein expression comparing non-IR with IR-
GFP and IR-CERE treatment. There was a clear decrease in the pres-
ence of protein SMGc, an embryonic mucin expressed in a subset of
SMG proacinar cells31 (Figures 3B and 3C), with IR-GFP and an in-
crease with IR-CERE, which may reflect increased acinar differentia-
tion with CERE-120 treatment. In addition, there was an increase in
stromal MMP2 expression with IR-GFP, potentially involved in
ECM remodeling associated with fibrosis after IR. The MMP2rapy: Methods & Clinical Development Vol. 18 September 2020 843
Figure 3. CERE-120 Treatment Reduces Levels of IR-Induced Fibrosis, Immune Response, and Innervation and Increases Proacinar Marker SMGc.
(A) Fold changes in gene expression of stromal/ECM remodeling, immune, and epithelial-related genes in AAV2-GFP (1010 vp/g) and CERE-120 (108 vp/g) pre-IR treated
glands. Data were normalized toGapdh and non-IR glands (dotted line). Mean ± SEM, N > 3. ANOVAwith post hocDunnett’s test. **p < 0.01, *p < 0.05, as compared to non-
IR. (B–G) Confocal imaging of SMGs of non-IR, AAV2-GFP 1010 vp/g, andCERE-120 108 vp/g immunostained for (B) SMGc (magenta), E-cadherin (ECAD) (green), and nuclei
(blue). Scale bar, 10 mm. (C) Quantification of SMGc and ECAD staining. (D) Immunostained for MMP2 (red), ECAD (green), and nuclei (blue). Scale bar, 20 mm. (E)
Quantification of MMP2 and ECAD staining. (F) Immunostained for TUBB3-expressing neurons (green) and ECAD (red). (G) Quantification of TUBB3 and ECAD. All staining
was normalized to the non-IR SMGs and nuclei. (C–G) Graphs show mean ± SEM. N > 3 glands with at least 5 images collected per gland. ANOVA with post hoc Dunnett’s
test. ***p < 0.001, **p < 0.01, *p < 0.05 compared to non-IR.
Molecular Therapy: Methods & Clinical Developmentimmunostaining was reduced in the IR-CERE treatment group (Fig-
ures 3D and 3E). Finally, there was an increase in the relative inner-
vation of the gland after IR, as shown by tubulin3 (TUBB3) staining
(Figures 3F and 3G). The increase of innervation after IR has been re-
ported previously and may reflect a reduction of epithelium with IR
combined with the survival of radiation-resistant nerves that appears
as an increase in TUBB3 staining.8 In sum, the RNA-seq analysis sug-
gests that IR-CERE treatment results in gene expression patterns that
reflect increased matrix remodeling and an improvement in homeo-
stasis of both innate and humoral immunity.844 Molecular Therapy: Methods & Clinical Development Vol. 18 SeptePreclinical Porcine PG Studies of CERE-120 Treatment Pre-IR
We then tested CERE-120 treatment pre-IR using the PGs of the Yuca-
tanminipig.WedeliveredAAV2-GFPorCERE-120 into the right-hand
side PG of each animal via retrograde ductal injection. One week later,
the AAV2-treated gland received a single dose of 15 Gy IR (Figure 4A),
which has been used previously to induce chronic hyposalivation by
4 weeks post-IR.20 Control groups consisted of AAV2-GFP (109 vp/g)
and CERE-120 (109 vp/g) treatment of non-IR PGs, as well as AAV2-
GFP (1012 vp/g) treatment a week before PG IR. Experimental treat-
ment groups included IR-CERE in increasing doses (108, 109, 1010,mber 2020
Table 2. DEGs from RNA Sequencing Analysis of Murine SMGs: IR-GFP
versus IR-CERE Treatments










































Data of each group was compared to one another. The lists of differentially expressed
genes (DEGs) were generated after bioinformatic analysis of next-generation
sequencing data and a cut-off at Log2 fold change (FC) and adjusted p values < 0.05.
There were 38 DEGs comparing IR GFP with IR-CERE.
Table 3. DEGs from RNA Sequencing Analysis of Murine SMGs: Non-IR
versus IR-CERE Treatments






























Data of each group was compared to one another. The lists of differentially expressed
genes (DEGs) were generated after bioinformatic analysis of next-generation
sequencing data and a cut-off at Log2 fold change (FC) and adjusted p values < 0.05.
There were 29 DEGs comparing non-IR with IR-CERE.
aGenes not present in Table 1
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Molecular The1011, and 1012 vp/g) delivered in 3 mL of sterile saline a week before IR.
Every 2 weeks post-IR, pilocarpine-stimulated glandular saliva produc-
tion was collected by cannulation of each PG (bilaterally), up to the
16 weeks conclusion of the experiment (Figure 4A). At the end of the
experiment, the PGs were removed and a dramatic reduction in gland
size and weight of all IR PGs was noted (Figure 4B), whereas the weight
of the animals was not significantly different (Figure 4C). Compared to
the non-IR groups treated with AAV2-GFP (G) or CERE-120 (CE), all
IR glands regardless of the treatment showed significant decrease in
gland weight (Figure 4D). Normalized gland weights (gland weight/
animal weight) showed a similar result, except IR-CERE-120
1011 vg/g showed no difference compared to non-IR-GFP (Figure 4E).rapy: Methods & Clinical Development Vol. 18 September 2020 845
Table 4. GO Pathway Analysis: Non-IR versus IR-GFP and IR-GFP versus
IR-CERE Treatments
Gene Ontology Term





Secretion (GO: 0046903) 12 3.82E02
Synapse (GO: 0045202) 10 3.82E02
Regulation of anatomical structure size (GO:
0090066)
7 3.82E02
Regulation of cellular protein localization
(GO: 1903827)
7 3.82E02
Intracellular transport (GO: 0046907) 12 3.82E02
IR-GFP versus IR-CERE
Extracellular matrix (GO: 0031012) 11 8.41E10
Collagen containing extracellular matrix (GO:
0062023)
9 3.40E08
Leukocyte mediated immunity (GO: 0002443) 12 3.30E09
Humoral immune response (GO: 0006959) 8 1.78E07
Myeloid leukocyte mediated immunity (GO:
0002444)
7 8.34E05
Secretory granule (GO: 0030141) 11 3.40E08
Secretion (GO: 0046903) 10 1.03E04
Complement activation (GO: 0006956) 7 6.08E08
GO pathway analysis of the gene lists from Tables 1, 2, and 3. Themost highly significant
GO terms were for the DEGs from Table 2, comparing IR-GFP with IR-CERE. There
were no significant GO terms for the list of DEGs from non-IR and IR-CERE.
Molecular Therapy: Methods & Clinical DevelopmentThe contralateral non-treated PGs retained their normal weight as
expected, since they did not receive IR or AAV2 vector (Figure 4F).
There was variability among PG weights; for example, with IR-CERE-
120, some PGs did increase in weight compared to IR-GFP (1 PG
with 109 and 2 PGs with 1010 vg/g), although overall this was not signif-
icant. CERE-120 treatment increased NRTN protein expression, which
was detected by immunostaining in clusters of cells of the IR PGs at
16 weeks post-treatment (Figure S3A). As expected, AAV2 viral parti-
cles were still detectable by qPCR in small biopsies of the PGs at the
end of the experiment at 16 weeks and in murine SMGs after
300 days (Figures S3B and S3C), indicating that both AAV2-GFP and
CERE-120 treatments persist for a prolonged time.
IR-Induced Alterations in Acinar Diameter and Ductal Marker
Expression Are Restored by CERE-120 Treatment Pre-IR
Histological analysis of PGs stained with H&E and MT stain (Figures
5A and 5B) showedmorphological changes with increased acinar size,
similar to murine SMGs (Figure 2). For brevity, we only show images
of IR-CERE 109 treatment. Furthermore, IR-CERE treatment had a
beneficial effect and resulted in a more similar morphology to non-
IR PGs (Figures 5A and 5B). Periductal and perivascular fibrosis
was observed byMT staining with dark blue deposits of collagen-con-
taining connective tissue in all treatment groups (Figure 5B). Interest-
ingly, Keratin 19 (KRT19)-expressing ducts appeared to be smaller in
size with fewer present in the IR-GFP-treated PGs compared to non-846 Molecular Therapy: Methods & Clinical Development Vol. 18 SepteIR or IR-CERE treatment (Figures 5B and 5C). The tissue was domi-
nated by enlarged acini structures that were easily observed with MT
staining (Figure 5D, yellow Ac). These enlarged structures were also
highlighted by enlarged luminal membranes and prominent areas
of localization of the apical water channel aquaporin5 (AQP5) and
E-cadherin (Figure 5E). Additionally, the acinar structures were high-
lighted by surrounding ACTA2-expressing myoepithelial cells (Fig-
ure 5F), and measurement of the acinus diameter showed that treat-
ment with CERE-120 at 3 different doses reduced their size similar to
the non-IR group (Figure 5G). Analysis of gene expression by qPCR
was more variable in the porcine PG than murine SMG. This may be
due to small biopsies to make cDNA from the large porcine PG that
may not be representative of the entire gland, whereas the entire mu-
rine SMG is lysed for analysis. There is likely more regional variation
in these small PG biopsies; for example, we avoided areas of the PG
for biopsy where white spongy fibrotic fat was present, as RNA yields
were negligible and of poor quality from these fibrotic biopsies (data
not shown). Analysis of gene expression by qPCR of a few of the genes
we had identified in the murine SMG were altered and showed a
reduction in expression of acinar markers AMY2 and AQP5 with
IR-GFP and an increase with IR-CERE treatment. In contrast, ductal
markers such KRT19 and CFTR increased with IR and reduced
expression with IR-CERE treatment compared to non-IR-GFP-
treated glands (Figure 5H). This highlights that the reduced KRT19
protein localization was associated with increased KRT19 gene
expression. Taken together, these data suggest that IR-induced
changes in acinar morphology and gene expression are restored by
CERE-120 treatment to levels similar to control in the porcine PG.
IR-Induced Alterations in Neuronal, Stromal, and Immune Cells
Are Restored by CERE-120
We used immunostaining and qPCR analysis to investigate changes
to the porcine PG nerves. We immunostained PGs with antibodies
to TUBB3, which labels neurons; KRT19, which labels ducts that neu-
rons are often associated with; and peanut lectin (PNA), which stains
the basement membranes surrounding acinar structures. There was
reduced TUBB3 staining with IR-GFP compared to their non-IR-
GFP and IR-CERE treatments (Figure 6A, lower panels, and Fig-
ure 6B). This finding is in contrast to what happened in the murine
SMGs, where there was an increase in neuronal staining (Figure 3F).
In addition, IR PGs treated with CERE-120 had similar levels of stain-
ing for nerves within lobules of the gland, and lower doses (e.g., 109
vp/g) were similar to the non-IR group. Interestingly, hyperinnerva-
tion (i.e., thickened nerve bundles) were observed in periductal areas
near large inter- and intra-lobular ducts with CERE-120 treatment
(Figures S4A–S4D). There was also a reduction in KRT19 staining
with CERE-120 1010–11 vp/g treatment. Quantitation of the PNA
and KRT19 staining showed a reduction with IR-GFP and an increase
to control levels with IR-CERE at lower doses. Analysis of gene
expression of neuronal genes by qPCR showed that there was no
change in expression ofTUBB3message in any group. These data sug-
gest that while CERE-120 increased neuronal staining after IR, there
was an overall reduction in TUBB3 mRNA levels. There was reduced
expression of tyrosine hydroxylase (TH), a marker of the sympatheticmber 2020
Figure 4. CERE-120 Treatment Pre-IR Does Not
Increase the Weight of the IR PG, but the
Contralateral Gland Is Similar to Non-IR Control.
(A) Schematic illustration of the study design with 52 ani-
mals. AAV2-GFP or CERE-120 gene therapy was delivered
to one PG in each animal pre-IR. One week later, animals in
the IR group received 15 Gy of radiation to the treated
gland. Saliva was collected bi-weekly until 16 weeks, when
tissues were harvested for analysis. (B) Representative im-
ages of the parotid salivary gland at the 16-week time point
from various groups (non-IR-GFP, IR-GFP, and IR-CERE
[109 and 1011]). Scale bar, 5 cm. (C–G) Graphs representing
animal weight (C), gland weight of the treated side (D),
normalized treated gland weight (data from C/data from D)
(E), gland weight of the contralateral non-treated side (F),
and normalized contralateral non-treated gland weight
(data from F/data from D) (G). Mean ± SEM. Dots represent
data from individual animals. N > 4. ANOVA with post hoc
Dunnett’s test, ***p < 0.001, **p < 0.01, *p < 0.05, not
significant (ns), as compared with non-IR-GFP.
www.moleculartherapy.orgnerves, althoughGFRA2, a marker of the parasympathetic nerves, was
not reduced with IR, and both markers with CERE-120 treatment
were similar to that of non-IR-GFP glands (Figure 6C).
We used qPCR to determine if IR-induced changes inmarkers of stro-
mal/ECM remodeling and immune cells occurred in porcine PGs
similar to murine SMGs (Figure 3A). We analyzed expression of
some stromal and immune genes by qPCR; these included SERP-
ING1, LYZ (the porcine version of Lyz2 in the mouse), MMP2, and
C3. Expression of SERPING1, LYZ, and MMP2 was increased in
IR-GFP PGs and was restored to levels comparable to that of non-
IR-GFP glands with CERE-120 treatment (Figure 6C). Expression
of C3 did not increase with IR-GFP and remained similar to control
levels with IR-CERE treatment. Since our GO analysis of murine
SMGs had suggested that a significant number of genes associated
with leukocyte immunity were altered, we immunostained the
porcine PGs for CD45, a receptor-linked tyrosine phosphatase that
is expressed on all leukocytes.32 As expected, non-IR-GFP PGsMolecular Therapy: Methods & Clinshowed staining of the occasional CD45+ leuko-
cyte in the interstitial spaces around the acinar
structures (Figure 6D). However, IR-GFP treat-
ment increased CD45 staining (Figures 6D and
6E), which appeared in large fibroblast-like cells
in the interstitial spaces. These cells may be
CD45+ fibrocytes or macrophages, which may
be responding to IR damage of the tissue or the
fibrotic response. Thorough characterization of
the porcine immune cells that respond to IR
will be an important future research goal. The
appearance of these cells was reduced with IR-
CERE treatment, and the morphology of the
CD45+ cells appeared similar to the non-IR-
GFP group, suggesting immune homeostasismay have been restored (Figures 6D and 6E). Together, these data
suggest that IR treatment reduces innervation of the porcine PG, re-
duces KRT19 duct cells, and increases markers of immune cells, all of
which return to control levels after IR with the lower doses of CERE-
120 treatment.
Low Doses of CERE-120 Prevent IR-Induced Hyposalivation in
the Minipig
Over the 16 weeks of observation after CERE-120 treatment, the stim-
ulated saliva volume of each gland (treated and contralateral) was
measured in individual animals every 2 weeks. There was large vari-
ation with the stimulated saliva flow collected from an individual an-
imal at each time point, so the volumes collected from 2–16 weeks
were averaged and compared to baseline levels before IR (100%,
dotted line) to generate summary graphs of the treated gland
compared to the contralateral gland (Figures 7A and 7B). Non-IR-
CERE-treated PGs showed similar saliva flow compared to non-IR-
GFP-treated PGs (Figure 7A). As expected, IR-GFP-treated PGsical Development Vol. 18 September 2020 847
Figure 5. IR-Induced Alterations in Acinar Morphology and KRT19+ Ducts in Porcine PGs Are Prevented by CERE-120 Treatment before IR.
(A and B) Representative pictures of H&E and Masson trichrome (MT) staining on glands from various groups (non-IR-GFP, IR-GFP, and IR-CERE 109 groups). Scale bar,
50 mm. (C) Single 2 mmconfocal sections of glands stained for Keratin 19 (red). Scale bar, 100 mm. (D) Pictures of MT staining showing enlarged acinar-tubular structures with
(legend continued on next page)
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www.moleculartherapy.orgshowed 60%–65% reduction in saliva flow. Importantly, IR-CERE-
treated PGs, in particular with the lower doses (108, 109, and 1010 vp/
g), increased their average saliva flow, except for the 1011 vp/g group.
It should be noted that some individual porcine PGs in the IR-CERE
groups had similar saliva flow to the non-IR-GFP controls. While the
contralateral gland did not receive any AAV2 vector or IR and were
the same weight as non-IR-GFP PGs (Figure 4F), the saliva flow
mimicked the pattern of the treated contralateral PG across all groups
(Figure 7B). Due to the changes in saliva flow of the contralateral
gland, we did not use the contralateral as control, instead averaging
flow and comparing to the IR-GFP group.
To take a closer look at the temporal pattern of saliva flow in the
treated and contralateral gland, we show the output of both glands
within the animal groups over the 16-week experimental timeline.
This highlights that with IR-GFP, the reduction in saliva flow begins
within 2 weeks and is below 50% of baseline flow (%50% hyposa-
livation is shown as a gray shaded area with dotted line in each
graph of Figure 7C) within 4 weeks and remained relatively stable
over time (IR-GFP) (Figure 7C). The analysis also shows the indi-
vidual variation of stimulated saliva flow at each time point and
that non-IR-CERE results in over 200% of flow after 8 weeks. The
highest dose of CERE-120 (1012) did not show improved salivary
flow at the end of the experiment, and saliva flow decreased over
time. The CERE-120 (1011) treatment did not improve saliva flow
at any stage and appeared similar to IR-GFP. In contrast, the lower
range of CERE-120 (108, 109, and 1010)-treated glands remained
well above 50% of salivary flow (Figure 7C). Particularly after
16 weeks in the 108 and 109 groups, saliva flow showed similar
values to those obtained from non-IR-GFP-treated glands. In
conclusion, CERE-120 treatment before IR prevents the long-term
effects of salivary hypofunction caused by IR and is most effective
at low doses of viral delivery.
DISCUSSION
Here we show that retro-ductal infusion of CERE-120 into murine
SMGs and porcine PGs prior to IR reduces the IR-induced salivary
gland hypofunction and restores immune homeostasis. Analysis of
murine SMGs 10 months after IR-CERE treatment showed there
was reduced expression of many genes associated with the extracel-
lular matrix and both the innate and adaptive humoral immune
response. In porcine PGs, CERE-120 gene therapy improved salivary
function and reduced the IR-induced alterations in acinar structure to
control levels 16 weeks after IR. We confirmed there was also a reduc-
tion of IR-related immune response and fibrosis and an improvement
of secretion with CERE-120 treatment in porcine PGs. Together, our
results suggest CERE-120 may potentially be useful as gene therapy to
prevent IR damage to salivary glands.IR-GFP. Scale bar, 40 mm. (E) Confocal imaging of AQP5 (red), ECAD (green), and nucle
bar, 20 mm. (F) Maximum intensity projections of confocal sections of glands stained fo
diameter of an individual acinus. (G) Graph depicting the area of acinus diameter in gl
Dunnett’s test, ***p < 0.001, as compared to non-IR-GFP. (H) Gene expression of acina
test compared to non-IR-GFP.
Molecular ThePreviously, we showed NRTN treatment protected neuronal cells
from apoptosis after IR-induced damage, and there was improved
innervation, epithelial morphogenesis, and gene expression.8,9,12
However, we had used recombinant NRTN protein or adenovirus-
NRTN treatment for these studies, and their use in clinical settings
is unlikely. Recombinant NRTN has a low solubility and short half-
life,33 and adenoviruses may elicit immune responses,7 whereas
AAV2 is considered safe and causes minimal inflammation.23
Although cannulation is used clinically for imaging salivary glands
during a sialogram, sub-acute areas of reversible inflammation can
occur due to the procedure.23
In our murine studies, it is unclear whether the mechanism of action is
different between the groups treated with vector before IR compared to
after IR. Although pre-IR treatment was more effective at preventing
hyposalivation at 90 days, the treatment after IR does show some strik-
ing positive effects in individual animals, althoughmore variable at 120
and 300 days. The variability may potentially be caused by infusion of
vector into a previously IR gland. Alternatively, post-IR treatment may
take longer to reestablish epithelial-neuronal interactions and commu-
nication among radiation-surviving neuronal and immune cells. Tak-
ing into consideration that even the slightest increase in saliva produc-
tion can translate in the subjective sensation of no longer having a dry
mouth,34 any increase in saliva flow above post-IR levels may clinically
be perceived as beneficial for patients.
We then showed that CERE-120 treatment had similar effects on
morphology and function in the porcine PGs. The AAV2 viral vector
has been used for gene therapy because of its long-term persistence,
and we detected AAV2 at the end of both murine and porcine exper-
iments in salivary glands (Figures S3B and S3C). CERE-120 has been
used for the potential treatment of Parkinson’s disease,35 and long-
term safety of the vector in phase I/II clinical trials was shown up
to 2 years.15 Also, in Parkinson’s-diseased rat brains, CERE-120 could
be detected up to 18–20 months, and in monkeys up to 2 years, after a
single treatment.36 In these conditions, no antibodies against the
NRTN protein were detected. Interestingly, the treatment of rat Par-
kinson’s disease was equally effective in aged rats. It will be important
to confirm the effects of CERE-120 on aged salivary glands, as there is
a growing geriatric population suffering from head and neck cancer. It
also remains to be determined whether the beneficial effects of CERE-
120 affect secretory function of other exocrine and endocrine glands,
such as lacrimal glands and pancreas.
A surprising finding in our porcine studies was that lower doses of vi-
rus (108–10 vp/g) were as effective if not better than the higher doses to
increase saliva flow, whereas in mice SMGs all three doses (106, 108,
and 1010 vp/g) were similar in effect. With higher vector doses ofi (blue) highlight the large luminal membranes of the enlarged acini structures. Scale
r AQP5 (red), SMA (green), and nuclei (DAPI). Scale bar, 10 mm. Arrows indicate the
ands from different treatment groups. Mean ± SEM. N > 3. ANOVA with post hoc
r and ductal-related markers. Mean ± SEM. N > 4. ANOVA with post hoc Dunnett’s
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Figure 6. IR-Induced Changes in Neuronal, ECM Remodeling, and Immune Cells Are Restored by CERE-120 Treatment before IR in Minipigs.
(A) Representative confocal images of PGs from non-IR-GFP, IR-GFP, and IR-CERE (1011, 1010, and 109 vp/g) stained for TUBB3 (yellow), KRT19 (red), Peanut Agglutinin
(PNA) (gray), and nuclei (blue). The TUBB3 channel is shown in the lower panels for clarity. Scale bar, 100 mm. (B) Quantification of immunostaining showing fold increase in
staining compared to non-IR-GFP. Graphs show mean ± SEM. N > 3 pigs with a minimum of 3 images collected per sample. ANOVA with post hoc Dunnett’s test. ***p <
0.001, *p < 0.05 compared to non-IR-GFP. (C) Fold changes in gene expression of neuronal genes, TUBB3,GFRA2, and TH; genes involved in ECM remodeling and fibrosis,
SERPING1 andMMP2; and immune-related genes,C3 and LYZ. Data were normalized to RPS29 and non-IR glands (dotted line). Graphs showmean ± SEM. N > 3. ANOVA
with post hocDunnett’s test. ***p < 0.001, **p < 0.01, *p < 0.05 compared to non-IR. (D) Confocal images of PGs from non-IR-GFP, IR-GFP, and IR-CERE 1010 vp/g, stained
for the leukocyte marker CD45 (green), ECAD (magenta), and nuclei (blue). Scale bar, 10 mm. (E) Quantification of CD45 normalized to the non-IR-GFP PGs. Graphs show
mean ± SEM. N > 3. ANOVA with post hoc Dunnett’s test. **p < 0.01 compared to non-IR.
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Figure 7. Low Doses of CERE-120 Gene Therapy Pre-IR Prevents IR-Induced Hyposalivation in Porcine PGs.
(A and B) Pilocarpine-stimulated saliva collected from the treated (A) and contralateral (B) parotid salivary gland was collected every 2 weeks. Saliva collected from 2–
16 weeks was averaged and normalized to the baseline (dotted line, 100%). Mean ± SEM. N = 4–8 animals per group. ANOVA with post hoc Dunnett’s test. *p < 0.05, ***p <
0.001, not significant (ns) when comparedwith non-IR-GFP group. (C) Time-course of saliva flow for various treatment groups. Black line, AAV2-treated gland. Gray line, non-
IR non-treated contralateral gland. The gray area with dotted line represents %50% reduction in flow from baseline (100%). Mean ± SEM. N = 4–8 animals per group.
www.moleculartherapy.org1011 and 1012 vp/g in porcine PGs, saliva flow decreased at 16 weeks to
levels similar to the IR-GFP group (Figure 7C). Immunostaining and
histology showed increased periductal hyperinnervation along the
major ducts (Figure S4). Our previous ex vivo culture of fetal murine
SMG also showed that high doses of recombinant NRTN in themedia
resulted in loss of epithelial innervation as the nerves extended past
the gland and grew along the culture surface.9 It is likely that very
high levels of NRTN in vivo may not restore epithelial-neuronal ho-
meostasis after IR.
Another interesting observation inminipigs was the coupled functional
behavior of the contralateral and treated PGs within one animal, evenMolecular Thethough the weight (Figure 4F) and histology of the contralateral gland
appears normal after IR. Previous reports showed that 16weeks after IR
there was a 60% reduction in the IR gland and a modest 17% reduction
in flow of the contralateral gland.19,21,37 Here, we quantitated the sali-
vary flow of both glands for all groups. Surprisingly, CERE-120 treat-
ment of a single non-IR PG increased saliva flow to a similar extent
in both PGs, and generally any CERE-120 treatment resulted in similar
trends in the salivary flow over time, whether up or down. There are a
number of possible mechanisms. The coupled functional behavior may
be due to central control of both PGs where regulatory feedback from
one gland affects the other. Alternatively, a systemic secreted factor
from a damaged gland or as a response to an improvement inrapy: Methods & Clinical Development Vol. 18 September 2020 851
Molecular Therapy: Methods & Clinical Developmenthomeostasis may influence both glands’ function. Our data also sup-
port a role for both the innate and the adaptive humoral immune sys-
tem in the response to CERE-120, and this may be controlled by im-
mune surveillance/function in both glands. Further investigation of
potential neuronal immune function in response to CERE-120 and
to both damage and repair is required.
NRTN is associated with inflammatorymechanisms in various mouse
asthma models and may orchestrate inflammatory changes by linking
the immune system with the nervous system in airway remodel-
ing.38,39 NRTN-deficient mice have increased T helper 2 (Th2) cyto-
kine secretion, airway inflammation, and airway hyper-responsive-
ness and, when sensitized, showed increased collagen deposition
and higher levels of neutrophils, matrix metalloproteinase 9
(MMP9), tumor necrosis factor alpha (TNF-a), and interleukin-6
(IL-6).39 Furthermore, recombinant NRTN prior to the allergen chal-
lenge partially rescued the phenotype. Here, we show that IR
increased expression of genes associated with the immune response,
and CERE-120 treatment reduced expression to control levels (Fig-
ures 3 and 6). IR increased CD45 staining, which marks all the leuko-
cytes, and large CD45+ cells, likely fibrocytes or macrophages, sur-
rounded acinar cells in IR-GFP glands. The treatment with CERE-
120 reduced the immune response, and the CD45+ cells appeared
similar to those in non-IR-GFP PGs, suggesting a dampening of the
immune response and a return to homeostasis.
Multiple approaches targeting different cellular mechanisms have
been developed to treat IR-induced hyposalivation in minipigs,
such as AQP1 and Shh gene therapy and rapamycin drug ther-
apy.3,17,19,20 Only AQP1 gene therapy has progressed to phase I/II
clinical trials in humans.6 In the future, combination therapies that
target different mechanisms may be required to prevent and repair
IR-induced injury. Here, we present a key translational advance using
CERE-120 to prevent IR-induced hyposalivation in head and neck
cancer patients. Low-dose CERE-120 gene therapy to human salivary
glands before IR treatment may prevent and/or maintain function af-
ter IR by modulating communication among neuronal, immune, and
epithelial cells to prevent saliva hypofunction and restore immune
homeostasis of the remaining glandular tissue.
MATERIALS AND METHODS
AAV2 Vector Constructs
For all experiments we used the CERE-120 (AAV2-hNRTN) vector to
administer human NRTN to salivary glands. The vector was pro-
duced by Sangamo BioSciences. A similar vector expressing GFP
used as a control was purchased from Vector Biolabs (Cat# 7004).
In Vivo Mice Experiments
All murine experiments were approved by the National Institute of
Dental and Craniofacial Research (NIDCR) Animal Care and Use
Committee. Eight-week-old female C3H mice (National Cancer
Institute Animal Production Area) were used. The treatment groups
included injection of AAV2-GFP (1010 vp/g) or CERE-120 (106, 108,
or 1010 vp/g) 10 days pre-IR or 60 days post-IR. Each group consisted852 Molecular Therapy: Methods & Clinical Development Vol. 18 Septeof 5–10 mice. Baseline saliva (non-IR) was collected prior to vector
delivery or IR. To irradiate the salivary glands, each animal was placed
in a specially built Lucite jig. This jig immobilizes animals without
the use of anesthetics and allows IR to the head and neck region
only. Mice were irradiated in 5 fractions (6 Gy/day for 5 days) using
a Therapax DXT300 X-ray irradiator (Pantak). After IR, animals were
removed from the jig, housed (5 animals per cage) in a climate- and
light-controlled environment, and allowed free access to food and
water.
To deliver viral vectors into submandibular glands, mice were anes-
thetized with ketamine (60 mg/kg) and xylazine (8 mg/kg) intramus-
cularly, upon which vectors were delivered into both submandibular
glands by retro-ductal infusion. During the cannulation, 0.5 mg/kg
atropine was intramuscularly applied to inhibit saliva secretion in
order to increase transduction efficiency.
For saliva collections, mice were anesthetized as mentioned above,
followed by subcutaneous injection of pilocarpine at 0.25 mg/kg
body weight to stimulate saliva secretion. Whole saliva was collected
with a 75-mm hematocrit tube (Drummond) into 1.5 mL pre-weight
Eppendorf tubes for 20min and frozen immediately. After 10months,
mice were sacrificed in a carbon dioxide chamber and the glands were
removed for analysis. Saliva was collected from the mice prior to the
start of experiment (baseline/non-IR), at 90, 120, and 300 days.
Radiation of Porcine PGs
The Institutional Animal Care and Use Committee of Allegheny
Singer Research Institute approved all animal experimentation
described herein. As described in Wang et al.,20 only one porcine
PG was irradiated. Briefly, IR was delivered using a Siemens Primus
linear accelerator (Concord, CA, USA). Animals were sedated and
placed inside a vacuum form bag in the linear accelerator, and the
PG was custom fitted using a Cerrobend (Bolton Metal Products, Bel-
lefonte, PA, USA) to prevent the electron beam from hitting sur-
rounding tissues. Digital radiography of the targeted (right) PG and
non-targeted (left) parotid was adopted as previously described20 to
ensure irradiation to the targeted parotid and to confirm sparing of
the contralateral parotid from radiation. A 12 MeV electron beam
was used to deliver a single dose of 15 Gy to the gland. Following re-
covery from sedation, all pigs were returned to the husbandry unit.
Saliva Collection from Porcine PGs
Saliva from porcine PGs was collected as described in Wang et al.20
All saliva was collected in the morning, bi-weekly and blindly. Mini-
pigs were anaesthetized by intramuscular injection of a mixture of ke-
tamine (20 mg/mL) and xylazine (2 mg/mL), placed on an operating
table, and intubated in a prone position with a continuous infusion of
isoflurane (1%–1.5%). An intramuscular injection of pilocarpine
(1 mg/kg) was given to allow secretion of saliva. A 2 mL capacity
oral swab (Salimetrics, Carlsbad, CA, USA) was weighed and placed
covering the opening of the parotid Stensen’s duct in the buccal
corridor and mechanically secured. Saliva was collected by capillary
action for 10 min, and the oral swab was replaced when needed.mber 2020
www.moleculartherapy.orgThe swabs were weighed, and saliva volume was calculated by sub-
tracting the initial weight from the final weight.
Gene Delivery in the Porcine Model
This procedure was performed as previously described in Wang
et al.20 All gene transfer procedures were performed in the morning.
The animals were sedated, intubated, and positioned supine for can-
nulation of the Stensen’s duct. An intramuscular injection of 0.54 mg
atropine was given, and after 10 min a P50 catheter fused to a P10
catheter was inserted into the opening of right-hand side Stensen’s
duct and secured with Vetbond (3M Products, St. Paul, MN, USA).
CERE-120 or AAV2-GFP virus was infused into one gland of the an-
imal (treated gland). All infusions were made in a 3 mL volume of
sterile saline. The tubing was left in place for an additional 10 min
to allow diffusion of the vector from the needle tip following infusion.
Tissue Processing and Histological Analysis of Murine SMGs
and Porcine PGs
Salivary glands were dissected from the animals and weighed. For the
porcine PGs, 0.5–1.5 cm3 biopsies containing glandular tissue were
collected from three separate regions of each gland, one close to the
Stensen’s duct, one in the middle part of the gland, and the other at
edge of the gland. We avoided the abundant white fatty fibrotic tissue
in the IR glands due to low RNA yields. All samples were analyzed indi-
vidually, and the three biopsies were not pooled for immunohisto-
chemistry (IHC) or RNA analysis purposes. Histological differences
among the biopsies were observed by IHC analysis; for example, peri-
ductal regions were almost absent in samples taken at the edge of the
gland. The location of small biopsies from the large PG may influence
variability in qPCR data. The tissues were immediately fixed in 4%
paraformaldehyde (PFA)/PBS, and the remaining gland was fixed in
20 volumes of formalin per weight of gland. The tissue biopsies were
processed for conventional H&E and MT staining.
Immunostaining of Mouse and Porcine Salivary Glands
Paraffin-embedded tissue sections were analyzed for primary anti-
bodies specific for smooth muscle actin (SMA) (Millipore Sigma, St.
Louis, MO, USA, #A2547), AQP5 (Alomone, Jerusalem, Israel,
#AQP-005), E-cadherin (Cell Signaling Technology, Boston, MA,
USA, #3195), E-cadherin (BD Biosciences, San Jose, CA, USA,
#610182), KRT19 (DSHB, IA, USA, TROMA III), Fluorescein-labeled
Peanut Agglutinin (PNA) (Vector Laboratories, Burlingame, CA, USA,
#FL-1071), Smgc (LSBio, #aa518-530 LC-C154825), Neuron-specific
beta-III Tubulin (R&D, Tuj1#MAB1195), MMP2 (R&D, #AF1488),
Neurturin (R&D, MN, USA, #AF477), and CD45 (Abcam, #ab23910).
Mouse or porcine glands were embedded in paraffin, sectioned onto
slides (7 mm), dried at 60C, and de-paraffinized in xylene substitute
(Sigma, St. Louis, MO, USA) followed by re-hydration in graded
ethanol solutions. Tissue sections were subjected to heat-mediated
antigen retrieval using R-universal epitope recovery buffer (Electron
Microscopy Sciences, Hatfield, PA, USA) for 10 min at high pressure.
Sections were blocked for 1 h at room temperature with 10% heat-in-
activated donkey serum (Jackson ImmunoResearch Laboratories,Molecular TheWestgrove, PA, USA), 1% BSA (Sigma, St. Louis, MO, USA), and
Mouse on Mouse blocking reagent (Vector Laboratories, Burlingame,
CA, USA). The slides were incubated overnight at 4C with the
appropriate primary antibody, then washed with PBS containing
0.1% Tween-20 (PBST) and incubated with the respective dye-conju-
gated secondary antibodies (all from Jackson ImmunoResearch Lab-
oratories, Westgrove, PA, USA) and DAPI stain (EMD Millipore,
Billerica, MA, USA) for 1 h at room temperature. Following washes
with PBST, slides were mounted with Fluoro-Gel mounting medium
(Electron Microscopy Sciences, Hatfield, PA, USA). All slides were
imaged using the Zeiss 710 or 880 confocal microscopes. Images
were thresholded to quantify the area of each protein staining, and
the data were normalized to non-IR control. An average of five
randomly selected areas of glandular tissue was taken per sample
by a blinded observer and a minimum of three samples per group
were combined and analyzed.
qPCR
Tissue samples for real-time PCR analysis were collected from three
separate regions of the porcine PG and stored in RNAlater stabilizing
solution (Ambion, Houston, TX, USA). Tissue (25 mg) was homog-
enized in RNA lysis buffer using Fastprep-24 instrument with lysing
matrix D (MP Biomedicals, Irvine, CA, USA). Murine SMGs were har-
vested, minced, and lyzed by homogenization. RNA was subsequently
isolated using the RNAqueous-4PCR total RNA isolation kit and
DNase reagents according to the manufacturer’s instructions (Ambion,
Houston, TX, USA). cDNAwas generated fromDNase-free RNA sam-
ples, amplified, and gene expression was normalized to the house-
keeping gene RPS29 or Gapdh as previously described in Patel et al.40
RNA-Seq and Bioinformatics Analysis
cDNA libraries were produced from RNA of non-IR, pre-IR-GFP,
and pre-IR-CERE (108) mouse submandibular glands using the Nex-
tera XT method. Samples were run on an Illumina NextSeq500
configured for 37 paired-end (PE) reads. FASTQ files were extracted
using bcl2fastq, and the FASTQ files were further processed using the
snakemake/3.8 utility in the Biowulf2 cluster. Quality of the reads was
evaluated using the FastQC software. Read mapping against a recent
ENCODE mouse release was performed using the STAR v2.5.2a
aligner using the standard mode with mapping parameters derived
from the GENCODE project. Subsequently, the quality of the map-
ping was analyzed using the QoRTs_QC package, which generates
multiple statistics about the quality of the mapping and the samples.
DeSeq2 was used to performed statistical test analysis to assess differ-
ential gene expression (DGE) between groups with a log2 fold in
expression with the adjusted p value of <0.05, as previously described
in Athwal et al.41 RNA-seq data are available on the Gene Expression
Omnibus (GEO) website (GEO: GSE150112).
TaqMan PCR to Quantify AAV2 Vector Level in Salivary Gland
Tissues
To evaluate the AAV2 genome levels, tissue samples were analyzed
using real-time qPCR and TaqMan chemistry. Genomic DNA from
frozen tissue samples was extracted using DNeasy Blood & Tissuerapy: Methods & Clinical Development Vol. 18 September 2020 853
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and probes were used to measure the viral particles in genomic
DNA. As previously reported, primers detecting AAV2 ITR were
used:42 the forward ITR primer (50-GGAACCCCTAGTGATG
GAGTT-30) and the reverse ITR primer (50-CGGCCTCAGT
GAGCGA-30). The hydrolysis probe was labeled with fluorescein
(FAM) and quenched with BlackBerry quencher (BBQ) (AAV2
ITR probe, 50-FAM-CACTCCCTCTCTGCGCGCTCG-BBQ-30).
Another probe set was also designed using Beacon Designer soft-
ware (PREMIER Biosoft International, Palo Alto, CA, USA) to
detect the CMV enhancer in the AAV2 vector. The forward CMV
primer 50-GGAGTATTTACGGTAAACTG-30, the reverse CMV
primer 50-GTCCCATAAGGTCATGTA-30, and the hydrolysis
probe were labeled with FAM on the 50 end and quenched with
QSY on the 30 end (AAV2 CMV probe, 50-FAM-CAAGTGTATCA
TATGCCAAGTACGCC-QSY-30). Primers, probe, and oligonucleo-
tides were synthesized by Thermofisher (Waltham, MA USA).
qPCR was performed with the CFX96 Real-Time PCR detection sys-
tem (BIORAD, Hercules, CA, USA). PCRs were performed in a
25 mL final volume using TaqMan Universal PCR Master Mix
(Applied Biosystems, Waltham, MA, USA) supplemented with
1 mM each of primers and probes and 10 mL of template DNA (either
plasmid standard or extracted sample DNA). The PCR profile con-
tained a uracil-N-glycosylase (UNG) treatment at 50C for 2 min,
an initial denaturation step at 95C for 10 min, followed by 40 cycles
of denaturation at 95C for 30 s and 60C for 1 min. Each qPCR run
was controlled by a “No template” negative control performed in trip-
licate. As a positive control, and calculation of the standard curves,
eight serial dilutions of the plasmid standard pAc CMV pLAc (con-
taining 101–108 plasmid copies per 10 mL) were prepared and sub-
jected to qPCR analysis in triplicate. Data analysis was performed
with CFX Maestro software (BIORAD, Hercules, CA, USA) to
generate the standard curves and to determine the concentration of
AAV2 in the DNA samples by interpolation. To analyze the influence
of genomic DNA on the robustness of our PCR, defined numbers of
plasmid DNA molecules were spiked with various amounts of
genomic DNA extracted from non-IR salivary gland DNA.
Statistical Analysis
Values are expressed as mean ± standard error of the mean (SEM).
Data were log transformed and analyzed with an unpaired Stu-
dent’s t test (two-tailed) for comparing two groups or a one-way
ANOVA with Dunnett’s multiple comparisons test for more
than two groups. Treatment groups were compared to the non-
IR control (mouse experiments) or non-IR-GFP (porcine experi-
ments) using Prism 8.4 software (GraphPad, La Jolla, CA, USA).
Tables of DEGs were generated using the DESeq2 package and
the Wald test with Benjamini-Hochberg adjusted p values < 0.05
and Log2 fold change.
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